The human protein Elafin plays a key role against the inflammatory reaction typical of Celiac disease and researchers have developed a probiotic bacterium able to deliver Elafin in the gut of mice.
Celiac disease is an auto-immune pathology that occurs in individuals genetically predisposed to gluten intolerance. Affected people do not harbor the enzymes required to degrade gluten during digestion and inflammatory reactions are induced by this abnormal digestion which can lead to the destruction of the gut barrier that is essential for nutrients absorption.
Celiac disease causes chronic abdominal pain (diarrhea, cramps…) and predisposes to certain cancers (small intestine, lymphoma). Its prevalence is estimated between 1/500 and 1/300; no curative treatment currently exist and the only solution is a lifelong gluten-free diet.
Scientists from the French National Institute for Agricultural Research (INRA) and the French National Institute of Health and Medical Research (INSERM), along with Canadian and Swiss colleagues, have shown that Elafin is less abundant in patients with celiac disease than in healthy people. They identified that Elafin is capable of preventing the destruction of the gut barrier during inflammation, and that Elafin is able to interact with enzymes responsible for the abnormal breakdown of gluten: transglutaminase-2.
Consequently, Elafin reduces gluten toxicity.
These observations led the scientists to propose a way to deliver the missing Elafin in celiac patients with help of a harmless bacterium that is often present in food: a lactic bacterium strain (Lactococcus lactis), that scientists transformed in order to express Elafin.
The use of this strain, developed by the same teams from INRA and INSERM, enables a targeted and local production of Elafin, and represents a recent and innovative strategy. The first pre-clinical results pave the way to new therapies for Inflammatory Bowel Disease or IBD (no curative treatment exist).
In the present study, the scientists have administered this bacterium to gluten intolerant mice. They showed that the Elafin delivered by the probiotic decreases significantly the inflammatory reaction.
This strategy, patented by INRA in May 2013, opens promising prospects to treat celiac disease and gluten intolerance in general. The next step will consist in defining the mechanisms underlying the positive effects of elafin in celiac disease, and in the identification of bacteria that naturally produce proteins with anti-inflammatory properties similar to elafin.
Citation: Heather J. Galipeau, Michelle Wiepjes, Jean-Paul Motta, Jessica D. Schulz, Jennifer Jury, Jane M. Natividad, Ines Pinto-Sanchez, Daniel Sinclair, Perrine Rousset, Rebeca Martin-Rosique, Luis Bermudez-Humaran, Jean Christophe Leroux, Joseph Murray, Edgardo Smecuol, Julio C. Bai, Nathalie Vergnolle, Philippe Langella and Elena F. Verdu, 'Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders', American Journal of Gastroenterology, 8 April 2014. DOI : 10.1038/ajg.2014.48
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Why An Extra Planet Can't Be Hidden Behind The Sun Or Above The South Pole
- My Applied National Security Paper. Being President Isn't For Idiots.
- Why Has Organic Farming Flatlined?
- Hugh Hefner's Wife Was Not Poisoned By Breast Implants
- Top Scientists Chastise Greenpeace
- SYRINA: A Trojan Horse For Endocrine Disrupting Chemicals?
- The Daily Physics Problem - 5
- "So what was the precipitating event which caused your re-evaluation?..."
- "I try this one... I am a bit rusty, so my solution can be dramatically wrong. Given that B is uniform..."
- "wow! with a name like Wilhelmina Pelegrina, she can't do no wrong. also,some of the problems in..."
- "This is the best you could do? Golden Rice is in the public domain - the lack of any corporate..."
- "Dylan, okay first TL:DR, the answer is that for anything of 10 km upwards, months or a year or..."
- Happy World Hepatitis Day!
- Ovarian Cancer – Redux
- New York Is Second In Health Care Premiums, Last In Hospital Quality
- USPSTF Advisory on Skin Cancer Screening Provokes Concerns from Docs
- Cancer As Modern Lifestyle Disease? Only If There Was Processed Food 2 Million Years Ago
- Blood Test for Alzheimer’s: Close Or Hype?